12. The method of claim 1wherein the filtering comprises filtering the mixture of step (b) through a membrane having a pore size of about 50,000 Dalton to create a 50,000 Dalton filtered mixture.

13. The method of claim 12 further comprising filtering the 50,000 Dalton filtered mixture through a membrane having a pore size of about 2,000 Dalton to about 3,000 Dalton to create a 2,000 to 3,000 Dalton filtered mixture.

14. The method of claim 12 or claim 13 further comprising filtering the 50,000 Dalton filtered mixture or the 2,000 to 3,000 Dalton filtered mixture through a membrane having a pore size of $\leq$600 Dalton.

15. The method of claim 1 wherein the concentration of human milk oligosaccharides after purification in step (c) is about 1% to about 5% weight/weight.

16. The method of claim 15 wherein the concentration of human milk oligosaccharides is about 5% weight/weight.

17. A purified human milk oligosaccharide composition made according to the method of any one of the previous claims.

18. The purified human milk oligosaccharide composition of claim 17 comprising $\leq$5% lactose.

19. The purified human milk oligosaccharide composition of claim 17 or claim 18 as shown in Figure 5E and Figure 5F.

20. A method of preventing NEC in a subject in need thereof comprising administering to the subject an effective amount of purified HMO composition of any one of claims 17-19.

21. A method for decreasing systemic inflammation in a subject in need thereof comprising administering to the subject an effective amount of the purified HMO composition of any one of claims 17-19.